Corporate - Media & Press - Press Release
Arrayit receives landmark patent for multi-patient genotyping technology.
Sunnyvale, CA, July 6, 2005 – On July 5th, the United States Patent and Trademark Office (USPTO) awarded Arrayit a landmark patent in the field of genotyping and human diagnostics. United States Patent 6,913,879 entitled “Microarray method of genotyping multiple samples at multiple loci” gives the company a major patent position in the rapidly expanding medical diagnostics market. Based on pioneering research by the company’s Visiting Scholar Dr. Mark Schena, the 879’ patent teaches methods of genotyping many patients at once, rather than one patient at a time as with traditional approaches. TeleChem’s patented multi-patient methods are rapid, accurate and highly cost-effective. In one embodiment, the “Schena patent” places spots of patient DNA on a glass substrate, allowing as many as 100,000 patients to be screened in a single microarray test. The massively parallel multi-patient format reduces the cost of genotyping by 1,000-fold and ensures 100% accuracy. In another embodiment, the multi-patient microarrays are manufactured using TeleChem’s widely used contact printing technology (U.S. 6,101,946), providing the customer with seamless patented integration of both manufacturing and genotyping. By virtue of 879’ patent issuance, TeleChem is well positioned to address the expanding $22 billion global in vitro diagnostics market.
At a recent press conference, Dr. Schena shared his views on multi-patient genotyping technology. “Most of my previous scientific work has focused on studying gene activity through gene expression analysis, rather than examining gene sequences by genotyping. But in the late 90’s we saw the need to develop genotyping methods that would allow testing of many patients at once, as a means of providing detailed information on genetic markers indicative of drug metabolism, neonatal disease, and other factors that impact human health. An ideal genotyping technology would allow many patients to be screened in a highly parallel manner. The eureka moment came some years ago when it occurred to me that an “upside down” microarray, with the patient DNA attached to the glass rather than in solution, would be one way in which thousands of patients could be screened simultaneously using a single testing device. Similar to computer chips that process many logic operations at once, multi-patient microarrays allow as many as 100,000 patients to be tested in a single operation. This technology would allow us to screen the entire population of the United States quickly and affordably.” Co-founder and company Vice-President Todd Martinsky provided additional insight. “There are two ways to genotype by microarray – patients up and patients down. The patients down 879’ patent basically gives us ownership of half the microarray genotyping market. It is an enviable position to be in as the market places increasing demands on affordable genotyping information for many patients. Our platform is ideally suited for testing laboratories of all shapes and sizes. We look forward to licensing our technology to current and new users.”
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.